Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215450 | 0.88 | OPRM1 (0.36) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15854187 | 0.86 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15854165 | 0.86 | OPRM1 (0.40) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL22271721 | 0.85 | APP (0.44) | — | |
| SCHEMBL15854190 | 0.85 | OPRM1 (0.36) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28388683 | 0.85 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28388684 | 0.84 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28390001 | 0.81 | OPRM1 (0.41) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15853775 | 0.79 | OPRM1 (0.46) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17216044 | 0.75 | PDE4D (0.36) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | OPRM1 683/4885OPRD1 473/4885OPRK1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.